AXONIS Therapeutics
Latest round
- Series A
Last raised
- Oct 2024
Total raised
- $46M
Investors
- 15
About AXONIS Therapeutics
AXONIS Therapeutics specializes in developing innovative therapies aimed at KCC2, a key mediator in the central nervous system. Founded in 2019 and headquartered in Boston, US, the company has engaged in 4 significant deals.Axonis Therapeutics focuses on developing therapies that target KCC2, with its leading product AXN-027 being an oral KCC2 potentiator that aims to restore functional inhibition and address neurological disorders such as epilepsy and chronic pain. Their products draw upon research from prestigious institutions, including Boston Children's Hospital and Harvard University, ensuring a solid scientific foundation. The company's revenue model relies on partnerships with pharmaceutical firms and research institutions, supplemented by grants and awards that bolster their developmental activities. As their products are still under development, transactions focus on strategic collaborations and research agreements rather than direct sales. The funds will be utilized to support the advancement of these new therapeutic options. The company plans to expand its market presence in North America and Europe, accelerating their product development paths with imminent clinical trials. The strategic focus is on enhancing their pipeline to address further neurological conditions, leveraging the financial backing received to expedite these initiatives.
Who invested in AXONIS Therapeutics
15 investors across 1 round
See all investors in AXONIS Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 31, 2024
Amount
$46M
Investors
Questions about AXONIS Therapeutics
Who invested in AXONIS Therapeutics?
AXONIS Therapeutics has 15 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AXONIS Therapeutics raised?
AXONIS Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AXONIS Therapeutics last raise money?
AXONIS Therapeutics's most recent round on record is a Series A, in Oct 2024.
What does AXONIS Therapeutics do?
AXONIS Therapeutics specializes in developing innovative therapies aimed at KCC2, a key mediator in the central nervous system.
Where is AXONIS Therapeutics headquartered?
AXONIS Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like AXONIS Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AXONIS Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like AXONIS Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.